Lido Advisors
UTHR icon

Lido Advisors’s United Therapeutics UTHR Stock Holding History

Lido Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$981K Buy
1,653
+1,009
+157% +$503K ﹤0.01% 975
2025
Q4 		$275K Buy
644
+69
+12% +$32.1K ﹤0.01% 1609
2025
Q3 		$241K Buy
+575
New +$193K ﹤0.01% 1600
2021
Q4 		– Sell
-1,554
Closed -$286K – 1050
2021
Q3 		$286K Buy
+1,554
New +$306K ﹤0.01% 766
2020
Q3 		– Sell
-2,116
Closed -$256K – 692
2020
Q2 		$256K Sell
2,116
-53
-2% -$5.96K 0.01% 489
2020
Q1 		$206K Buy
+2,169
New +$206K 0.01% 515

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Lido Advisors's UTHR Position: Q1 2026 in Review

Lido Advisors increased its United Therapeutics (UTHR) stake by 157% in Q1 2026, buying an estimated $503K and bringing the position to 1,653 shares worth $981K. The position accounts for ﹤0.01% of the portfolio, ranked #975.

Lido Advisors first reported a position in UTHR in Q1 2020 and has held it in 6 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Lido Advisors held 1,653 shares of United Therapeutics worth $981K as of Q1 2026.
  • Lido Advisors bought 1,009 United Therapeutics shares in Q1 2026, an estimated $503K.
  • United Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #975 holding.
  • Lido Advisors first reported a position in United Therapeutics in Q1 2020 and has held it in 6 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.